Moleculin's Annamycin cardiac safety data accepted for ASCO poster presentation

Moleculin Biotech announced that pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting, showing no statistically significant cardiotoxicity at high cumulative doses. The findings support the potential for Annamycin to provide effective anthracycline therapy without traditional dose limitations, strengthening the rationale for the ongoing pivotal MIRACLE trial in AML patients.